fibrosis » Trang Công Nghệ | Trangcongnghe.vn

Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide

Globe Newswire

Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide

Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

Globe Newswire

Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

Globe Newswire

Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis

Globe Newswire

Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for claudin-1 in cancer & fibrosis